Cancer Genetics (CGIX) Tops Q3 EPS by 5c

Cancer Genetics (NASDAQ: CGIX) reported Q3 EPS of ($0.23), $0.05 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $6.93 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Parsons Corporation (PSN) Tops Q2 EPS by 10c; Offers Guidance
• Trip.com Group Limited (TCOM) PT Lowered to $60 at BofA Securities
• Freedom Broker Downgrades Royal Caribbean Cruises (RCL) to Hold, 'Strong Quarter, but the Share Price Now Captures It'